Uncategorized

While disease-modifying therapies largely steal the spotlight in Alzheimer’s drug development, several companies are working to solve this less-discussed but disruptive facet of the illness.

Biostar Pharma, Inc. announced today that their core pipeline product utidelone injectable (UTD1) had been granted an Orphan Drug Designation (ODD) by the FDA for the treatment of breast cancer brain metastasis (BCBM).

The acquired assets generate about $100 million in annual revenue, according to the deal announcement.

Designed as an alternative to endoscopy, the cancer screening test uses a sponge collection device that’s paired with an algorithm.

The chairman of J&J subsidiary DePuy Synthes talked about how surgical robots and other technologies have contributed to procedures moving to outpatient facilities.

Sanders says he wants Novo Nordisk to “do the right thing” and lower the costs of Ozempic and Wegovy. But only the Inflation Reduction Act can achieve that.

Antitrust regulators filed this week to block the deal, a move akin to trying to stop a “ball that’s already rolling downhill,” one expert said.

McMahon announced earlier this year that he would retire from the healthcare behemoth in April. Rex will step up as president, though there’s no word yet on who will assume McMahon’s chief operating officer role.

U.S. intelligence officials have informed senators that China-based biotech WuXi AppTec transferred an American client’s intellectual property to the Chinese government without consent, reports Reuters.

The transformation, led by Deloitte Digital, focused on increasing customer feedback to identify pervasive issues and closing the loop on customer inquiries.